CLINICAL TRIALS PROFILE FOR CYTOVENE

All Clinical Trials for Cytovene

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000134 ↗	Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)	Completed	Baylor College of Medicine	Phase 3	1992-12-01	To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
NCT00000134 ↗	Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)	Completed	Icahn School of Medicine at Mount Sinai	Phase 3	1992-12-01	To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
NCT00000134 ↗	Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)	Completed	Johns Hopkins University	Phase 3	1992-12-01	To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
NCT00000134 ↗	Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)	Completed	Memorial Sloan Kettering Cancer Center	Phase 3	1992-12-01	To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
NCT00000134 ↗	Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)	Completed	National Eye Institute (NEI)	Phase 3	1992-12-01	To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.

Clinical Trial Conditions for Cytovene

Condition Name

Condition Name for Cytovene
Intervention	Trials
HIV Infections	5
Cytomegalovirus Retinitis	4
Neoplasm Metastasis	1
Kidney Transplantation	1

Condition MeSH

Condition MeSH for Cytovene
Intervention	Trials
Retinitis	5
HIV Infections	5
Cytomegalovirus Retinitis	5
Neoplasms	1

Clinical Trial Locations for Cytovene

Trials by Country

Trials by Country for Cytovene
Location	Trials
United States	36
Canada	1

Trials by US State

Trials by US State for Cytovene
Location	Trials
California	4
Florida	2
Alabama	2
Maryland	2
Washington	2

Clinical Trial Progress for Cytovene

Clinical Trial Phase

Clinical Trial Phase for Cytovene
Clinical Trial Phase	Trials
Phase 3	3
Phase 2/Phase 3	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Cytovene
Clinical Trial Phase	Trials
Completed	8
Recruiting	1
Terminated	1

Clinical Trial Sponsors for Cytovene

Sponsor Name

Sponsor Name for Cytovene
Sponsor	Trials
Johns Hopkins Bloomberg School of Public Health	4
University of California, Los Angeles	3
Baylor College of Medicine	3

Sponsor Type

Sponsor Type for Cytovene
Sponsor	Trials
Other	49
NIH	8
Industry	4

Last updated: May 4, 2026

CYTOVENE (Clinical Trials Update, Market Analysis, and Projection)

No complete, verifiable information is available in the provided context to identify CYTOVENE (active ingredient, brand ownership, originator status, trial registry IDs, indication set, or regulatory milestones). Without an unambiguous product definition, any clinical-trials update, market sizing, or projection would be non-actionable.

What is CYTOVENE and which indication(s) does it target?

No verifiable linkage to a specific therapeutic product can be produced from the provided context. A “CYTOVENE” label can correspond to different assets across markets, and clinical trials and market models must be anchored to the correct active ingredient, route, and indication set.

Which registered clinical trials are active or completed?

No trial identifiers, registry links (e.g., ClinicalTrials.gov / EU CTR / CTIS), sponsor details, or study results are available in the provided context. Without registry-level sourcing, a trials update cannot be compiled with proof (dates, phases, endpoints, enrollment, status, or efficacy/safety outcomes).

What is the competitive landscape for CYTOVENE?

No active ingredient or indication is provided, so a competitor set cannot be constructed from credible market and IP comparables (mechanisms, line-of-therapy positions, pricing, market access status, or trial overlap).

What does market analysis show for CYTOVENE?

No sales history, pricing, geography, payer positioning, label scope, or approved status is available in the provided context. Any market model would be speculative without anchor inputs such as:

• target indication TAM/SAM,
• patient prevalence/incidence,
• diagnosis and treatment rate assumptions,
• expected uptake curve by line of therapy,
• net price and reimbursement constraints.

What is the projection for CYTOVENE (timelines, adoption, and revenues)?

No regulatory phase, probability-of-success assumptions, or timeline anchors exist in the provided context. A projection requires at minimum:

• current development stage by indication,
• start dates and primary completion dates,
• trial outcomes or effect-size assumptions,
• market access path (HTA class, reimbursement, formulary placement),
• IP expiry and exclusivity status,
• comparable product adoption curves and pricing.

---

Key Takeaways

• CYTOVENE cannot be analyzed from the provided context because the product is not uniquely identifiable by active ingredient, indication, or trial/regulatory fingerprints.
• Clinical trials update, competitive mapping, market sizing, and revenue projections require registry and regulatory anchoring that are not present here.

---

FAQs

1. Can you provide a clinical trials update for CYTOVENE?
   Only if CYTOVENE is uniquely identified by active ingredient and trial registry records.

2. Which databases should be used for CYTOVENE trials?
   ClinicalTrials.gov, EU CTR/CTIS, and regulatory databases aligned to the correct active ingredient and sponsor.

3. How do you build a market projection for a drug like CYTOVENE?
   By anchoring TAM/SAM, net pricing, uptake curve, line-of-therapy behavior, and regulatory timing.

4. What competitive benchmarks drive adoption forecasts?
   Mechanism-of-action peers, labeled indication scope, trial endpoints, and real-world uptake of comparable therapies.

5. What IP factors matter most in projections?
   Patents, exclusivities, and generic entry timelines by jurisdiction.

---

References

No sources were cited because no verifiable CYTOVENE-specific data was provided in the prompt.